Payment overview · 2025
General Payments
$1,194.01
69 reported records · 18 companies
Healthcare provider profile · identity verified
Mark E Heinsohn, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHATTANOOGA, TN · NPI 1457338014
Verified facts
What the public records show
CMS Open Payments records show Mark E Heinsohn, MD received $1,194.01 in general payments during 2025 across 69 reported records.
PFIZER INC. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $194.12 | 16.3% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $185.64 | 15.6% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $163.62 | 13.7% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $119.17 | 10.0% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $112.67 | 9.4% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $109.27 | 9.2% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.21 | 4.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.58 | 3.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.94 | 2.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.71 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.30 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.70 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.97 | 1.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.74 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.67 | 1.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.36 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.22 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.12 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,194.01 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $171.72 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $171.72 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $138.14 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $133.54 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $116.53 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $116.53 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $112.67 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $109.27 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $100.56 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.56 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.06 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $41.58 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.98 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 255 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
255 | 65 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
255 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 512 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 504 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 468 | 145 |
| Losartan Potassium | Losartan Potassium | 468 | 137 |
| Omeprazole | Omeprazole | 442 | 137 |
| Gabapentin | Gabapentin | 415 | 71 |
| Sertraline Hcl | Sertraline Hcl | 402 | 120 |
| Lorazepam | Lorazepam | 364 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 354 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 351 | 104 |
| Potassium Chloride | Potassium Chloride | 330 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 324 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 49 |
| Clonazepam | Clonazepam | 292 | 36 |
| Eliquis | Apixaban | 255 | 65 |
| Metformin Hcl Er | Metformin Hcl | 236 | 72 |
| Montelukast Sodium | Montelukast Sodium | 227 | 72 |
| Lisinopril | Lisinopril | 223 | 54 |
| Furosemide | Furosemide | 211 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 67 |
| Azithromycin | Azithromycin | 209 | 133 |
| Famotidine | Famotidine | 193 | 68 |
| Carvedilol | Carvedilol | 192 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 86 |
| Simvastatin | Simvastatin | 187 | 53 |
| Alprazolam | Alprazolam | 179 | 41 |
| Donepezil Hcl | Donepezil Hcl | 174 | 58 |
| Atenolol | Atenolol | 165 | 48 |
| Meloxicam | Meloxicam | 161 | 52 |
| Prednisone | Prednisone | 160 | 59 |
| Trazodone Hcl | Trazodone Hcl | 158 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 157 | 46 |
| Ozempic | Semaglutide | 139 | 28 |
| Tramadol Hcl | Tramadol Hcl | 135 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 43 |
| Meclizine Hcl | Meclizine Hcl | 132 | 50 |
| Allopurinol | Allopurinol | 125 | 38 |
| Memantine Hcl | Memantine Hcl | 123 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 111 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 110 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 104 | 30 |
| Repatha Sureclick | Evolocumab | 98 | 16 |
| Valsartan | Valsartan | 97 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 34 |
| Cephalexin | Cephalexin | 90 | 67 |
| Methylprednisolone | Methylprednisolone | 88 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 83 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 81 | 14 |
| Clonidine Hcl | Clonidine Hcl | 80 | 27 |
| Spironolactone | Spironolactone | 79 | 24 |
| Synthroid | Levothyroxine Sodium | 79 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 14 |
| Diazepam | Diazepam | 77 | suppressed |
| Temazepam | Temazepam | 75 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 19 |
| Bupropion Xl | Bupropion Hcl | 73 | 22 |
| Promethazine Hcl | Promethazine Hcl | 73 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 25 |
| Finasteride | Finasteride | 71 | 24 |
| Cefadroxil | Cefadroxil | 69 | 25 |
| Pregabalin | Pregabalin | 69 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 20 |
| Warfarin Sodium | Warfarin Sodium | 68 | 21 |
| Buspirone Hcl | Buspirone Hcl | 66 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 18 |
| Fluconazole | Fluconazole | 59 | 38 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Celecoxib | Celecoxib | 55 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 55 | 22 |
| Glimepiride | Glimepiride | 55 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 16 |
| Sucralfate | Sucralfate | 53 | 17 |
| Methocarbamol | Methocarbamol | 52 | 15 |
| Novolog Flexpen | Insulin Aspart | 51 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 50 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 11 |
| Hydrocortisone | Hydrocortisone | 46 | 28 |
| Alendronate Sodium | Alendronate Sodium | 43 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 12 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Famciclovir | Famciclovir | 40 | 23 |
| Mupirocin | Mupirocin | 40 | 29 |
| Nystatin | Nystatin | 38 | 18 |
| Torsemide | Torsemide | 37 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Metformin Hcl | Metformin Hcl | 35 | suppressed |
| Cefprozil | Cefprozil | 34 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 19 |
| Ketoconazole | Ketoconazole | 34 | 15 |
| Amoxicillin | Amoxicillin | 32 | 16 |
| Benzonatate | Benzonatate | 32 | 14 |
| Indapamide | Indapamide | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Trimethoprim | Trimethoprim | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 15 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Colchicine | Colchicine | 21 | 12 |
| Estradiol | Estradiol | 21 | 13 |
| Estradiol (Twice Weekly) | Estradiol | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Cefuroxime | Cefuroxime Axetil | 20 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Bicalutamide | Bicalutamide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Phenytoin | Phenytoin | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,194.01 · 69 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, XIFAXAN, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error